2025-03-26

Leeford is a key player in the generic drug market. What key factors have driven your success in this segment?

Consistency in our quality and adherence to international manufacturing standards have become synonymous with Leeford in the Indian Pharmaceutical Market. We are steadfast in our commitment to offering consumers products that demonstrably meet the highest standards of efficacy and purity. Our success stems from a rigorous focus on delivering reliable, high-quality generics that patients and healthcare professionals can trust.

One of the biggest challenges in the pharmaceutical industry is maintaining high quality while keeping medicines affordable. How does Leeford strike this balance?

Quality is non-negotiable at Leeford. We achieve affordability through strategic procurement from premier suppliers, ensuring access to authentic raw materials. Our robust and meticulously managed supply chain, coupled with exceptional planning, allows us to optimise costs without ever compromising product integrity. We operate with efficiency and precision, ensuring accessibility without sacrificing excellence.

How is Leeford leveraging technology and digital transformation to improve drug development and manufacturing processes?

Leeford is committed to fully connected, safe, and operationally efficient processes. We employ centralised systems across all our manufacturing facilities, connecting people, processes, and data to enhance yield and productivity. This technological integration allows for real-time monitoring and optimisation, ensuring consistent quality and efficiency.

Are there any major expansion projects or new manufacturing facilities in the pipeline?

Leeford is continuously investing in scientific and technical excellence to develop and launch innovative products. We are actively expanding our presence in the Core Critical Care segment with the establishment of our own injectable manufacturing unit and a disposable surgical facility. Additionally, we are developing new OTC manufacturing facilities, all of which are slated for completion within the current year.

What steps is Leeford taking to strengthen its supply chain resilience? Do you foresee any major pricing pressures in the generics market, and how is Leeford preparing for them?

The pharmaceutical supply chain faces inherent vulnerabilities, particularly with reliance on imported APIs and specialty actives. Leeford mitigates these risks through meticulous planning and strategic inventory management. Our significant in-house manufacturing capacity, encompassing over 800 products, provides us with exceptional control and agility. Regarding pricing pressures, we remain vigilant and proactive. We are prepared to adapt through strategic cost optimisation and operational efficiencies, ensuring we maintain competitive pricing while upholding our uncompromising quality standards.

How do you see the pharmaceutical sector evolving in the next five to ten years, and how is Leeford preparing for these changes?

The pharmaceutical sector is undergoing a profound transformation, driven by groundbreaking therapies, technological advancements, and the consumerisation of healthcare. We are witnessing a shift from incremental evolution to a rapid revolution. Leeford is not merely adapting to these changes; we are driving them. We are integrating cutting-edge technologies into our manufacturing processes, marketing strategies, and supply chain operations. Furthermore, we are investing in data analytics and personalised medicine to anticipate and meet the evolving needs of patients. We are fostering a culture of innovation and agility, ensuring we remain at the vanguard of the pharmaceutical industry. We are also preparing for the increased role of AI in drug discovery, and personalised medicine, and are investing in those areas. Leeford is poised to lead the way in this new era of healthcare, delivering innovative and accessible solutions that improve patient outcomes and transform lives.